Could Vital Therapies Inc (NASDAQ:VTL) Change Direction After More Shorts?

June 14, 2018 - By Vivian Park

Investors sentiment decreased to 0.93 in 2018 Q1. Its down 1.92, from 2.85 in 2017Q4. It dropped, as 11 investors sold Vital Therapies, Inc. shares while 16 reduced holdings. 10 funds opened positions while 15 raised stakes. 11.17 million shares or 7.13% more from 10.42 million shares in 2017Q4 were reported.
Citigroup Incorporated owns 15,909 shares. 83,688 are held by Northern Tru. Element Management Ltd Llc holds 0% or 30,697 shares in its portfolio. Dowling Yahnke Ltd Co invested 0.01% in Vital Therapies, Inc. (NASDAQ:VTL). Geode Cap Management Ltd Liability Company invested in 0% or 192,788 shares. Artal Group Inc Sa stated it has 1.00M shares or 0.09% of all its holdings. Victory Capital Management Inc accumulated 2.99 million shares. The Guernsey-based Bluecrest Cap Management Limited has invested 0.01% in Vital Therapies, Inc. (NASDAQ:VTL). Millennium Mngmt holds 414,540 shares. Wells Fargo & Mn holds 675 shares or 0% of its portfolio. Bnp Paribas Arbitrage has 0% invested in Vital Therapies, Inc. (NASDAQ:VTL) for 926 shares. Retail Bank Of Montreal Can holds 0% or 19,864 shares in its portfolio. Raymond James & Assocs holds 0% or 36,682 shares. Blackrock accumulated 954,715 shares. Morgan Stanley accumulated 42,773 shares or 0% of the stock.

The stock of Vital Therapies Inc (NASDAQ:VTL) registered an increase of 1.62% in short interest. VTL’s total short interest was 6.36M shares in June as published by FINRA. Its up 1.62% from 6.26M shares, reported previously. With 158,600 shares average volume, it will take short sellers 40 days to cover their VTL’s short positions. The short interest to Vital Therapies Inc’s float is 23.41%.

The stock increased 1.33% or $0.075 during the last trading session, reaching $5.725. About 148,060 shares traded. Vital Therapies, Inc. (NASDAQ:VTL) has risen 101.77% since June 14, 2017 and is uptrending. It has outperformed by 89.20% the S&P500.

Vital Therapies, Inc., a biotherapeutic company, focuses on developing a human hepatic cell therapy targeting the treatment of acute forms of liver failure in the United States. The company has market cap of $242.56 million. The Company’s ELAD system is an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials to allow the patient??s own liver to potentially regenerate to a healthy state or to stabilize the patient until transplant. It currently has negative earnings. The firm was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003.

More important recent Vital Therapies, Inc. (NASDAQ:VTL) news were published by: Nasdaq.com which released: “Vital Therapies Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)” on June 12, 2018, also Globenewswire.com published article titled: “Vital Therapies Hosting Analyst R&D Day Today”, Nasdaq.com published: “Vital Therapies to Present at the Jefferies 2018 Global Healthcare Conference” on June 07, 2018. More interesting news about Vital Therapies, Inc. (NASDAQ:VTL) was released by: Equitiesfocus.com and their article: “Vital Therapies (NASDAQ:VTL) Earning Somewhat Favorable News Coverage, Analysis Shows” with publication date: June 14, 2018.

Vital Therapies, Inc. (NASDAQ:VTL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: